Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 20Terminated 8Recruiting 3Active not recruiting 3Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 15NIH 13INDUSTRY 2UNKNOWN 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphatic Diseases 1Leukemia 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24Cyclophosphamide 24icotinib 23Oxaliplatin 20fludarabine 19Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Nivolumab 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Daunorubicin × Clear all
NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡